Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Return to: PBR Home | Contract Research & Services
Today in Contract Research & Services

Contract Research & Services

BMS, PsiOxus Therapeutics to study immuno-oncology combination Bristol-Myers Squibb (BMS) and UK-based PsiOxus Therapeutics have agreed to work together on a new combination therapy targeting various tumor types in late-stage cancer patients. Contract Research & Services > Contract Research > News

Latest Contract Research & Services News by Sector

Select a sector from the list or browse by sector below:

Clinical Trials

GSK starts phase I oncology study with ICOS agonist antibody
By PBR Staff Writer
GSK has started a phase I clinical trial with GSK3359609, an investigational inducibile T-cell costimulator (ICOS) agonist antibody.
Contract Research & Services > Clinical Trials > News
Shire’s retinopathy treatment fails to meet primary endpoint in phase 2 trial
By PBR Staff Writer
A phase 2 clinical trial assessing Shire’s investigational protein replacement, SHP607, failed to meet its primary endpoint of reducing the severity of retinopathy of prematurity (ROP), a rare eye condition.
Contract Research & Services > Clinical Trials > News

Contract Research

BMS, PsiOxus Therapeutics to study immuno-oncology combination
By PBR Staff Writer
Bristol-Myers Squibb (BMS) and UK-based PsiOxus Therapeutics have agreed to work together on a new combination therapy targeting various tumor types in late-stage cancer patients.
Contract Research & Services > Contract Research > News
TB Alliance, Takeda partner to investigate novel compounds for tuberculosis treatment
The Global Alliance for TB Drug Development (TB Alliance) and Takeda Pharmaceutical Company have entered into an agreement that further explores hits generated from a high-throughput screening program conducted to find novel compounds to improve treatment of tuberculosis (TB).
Contract Research & Services > Contract Research > News

Contract Services

Clinigen, Horizon Pharma partner to start European Managed Access program for RAVICTI Oral Liquid
Clinigen Group's Idis Managed Access (MA) division and Horizon Pharma have initiated a Managed Access program in Europe for Horizon’s RAVICTI (glycerol phenylbuterate) Oral Liquid.
Contract Research & Services > Contract Services > News
Therapix signs binding MOU with Swiss pharmaceutical firm to receive License to use formulation for ultralow-dosage administration
Therapix Biosciences has entered into a binding memorandum of understandings with a Swiss pharmaceutical development company, to receive a worldwide and exclusive license to use the formulation for sublingual administration of ultralow dosages of THC, for the purpose of developing and marketing the formulation in the indications on which the Company has chosen to focus, with an emphasis on cognitive impairments.
Contract Research & Services > Contract Services > News